The Current Ratio as of November 2024 (TTM) for Resverlogix Corp. (RVXCF) is 0.11

According to Resverlogix Corp.’s latest financial reports and current stock price. The company's current Current Ratio is 0.11. This represents a change of -15.41% compared to the average of 0.13 of the last 4 quarters.

Resverlogix Corp. (RVXCF) Historical Current Ratio (quarterly & annually)

How has RVXCF Current Ratio performed in the past?

The mean historical Current Ratio of Resverlogix Corp. over the last ten years is 0.51. The current 0.11 Current Ratio has changed 2.02% with respect to the historical average. Over the past ten years (40 quarters), RVXCF's Current Ratio was at its highest in in the October 2014 quarter at 3.71. The Current Ratio was at its lowest in in the July 2017 quarter at 0.06.

Resverlogix Corp. (RVXCF) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Resverlogix Corp. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Resverlogix Corp. (RVXCF) Average Current Ratio

How has RVXCF Current Ratio performed in the past?

The current Current Ratio of Resverlogix Corp. (RVXCF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Resverlogix Corp. (RVXCF) Current Ratio vs. Peers

How is RVXCF’s Current Ratio compared to its peers?

Resverlogix Corp.’s Current Ratio is less than Cellectis S.A. (1.92), less than Biotron Limited (0.58), less than Small Pharma Inc. (4.88), less than Covalon Technologies Ltd. (5.24), greater than Bioasis Technologies Inc. (0), less than Fennec Pharmaceuticals Inc. (8.02), less than Biohaven Pharmaceutical Holding Company Ltd. (3.27), less than ImmunityBio, Inc. (3.91), less than Cadrenal Therapeutics, Inc. Common Stock (3.60), less than Foghorn Therapeutics Inc. (5.69), less than Comera Life Sciences Holdings, Inc. (0.90), less than Coya Therapeutics, Inc. (0), less than NewAmsterdam Pharma Company N.V. (10.43), less than Centessa Pharmaceuticals plc (9.83), less than Eliem Therapeutics, Inc. (13.29), less than Inhibrx Biosciences, Inc. (60.41), less than Merrimack Pharmaceuticals, Inc. (6.20), less than Celcuity Inc. (10.78), less than Enliven Therapeutics, Inc. (14.95), less than null (14.39),

Build a custom stock screener for Resverlogix Corp. (RVXCF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Resverlogix Corp. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Resverlogix Corp. (RVXCF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Resverlogix Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.